Clinical trialPhase 2Unknown
Study of S-1 as Second Line Treatment on Advanced Pancreatic Cancers
A Randomized , Open-label, Multicenter, Phase II Study to Compare the Efficacy of S-1 and S-1 Plus Leucovorin as Second Line Treatment on Gemcitabine-refractory Patients With Inoperable or Advanced Pancreatic Cancers
- Outcome
- Outcome unknown
- Phase
- Phase 2
- Status
- Unknown
- Study type
- Interventional
- Start
- February 2010
- Expected end
- July 2014
- Enrollment
- 92 participants
- Sites
- 1
- Primary outcomes
- Progression Free Survival(PFS)
- Sponsor
- Other
- Results posted
- No
- Last update
- 16 January 2014
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try